Results for karboanhydrase translation from Danish to English

syre- base forstyrrelser er rapporteret ved perorale karboanhydrase- hæmmere.
acid-base disturbances have been reported with oral carbonic anhydrase inhibitors.

karboanhydrase aktiviteten var ca.40-70% af niveauet før medicinering.
carbonic anhydrase activity was approximately 40-70% of predose levels.

azopt er et sulfonamid, en karboanhydrase-hæmmer, som absorberes systemisk.
azopt is a sulphonamide inhibitor of carbonic anhydrase with systemic absorption.

brinzolamid er en karboanhydrase-hæmmer som absorberes systemisk trods lokal administration.
azopt is a carbonic anhydrase inhibitor and, although administered topically, is absorbed systemically.

karboanhydrase katalyserer den reversible reaktion; hydreringen af kuldioxid samt dehydreringen af kulsyre.
carbonic anhydrase catalyses the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid.

azopt øjendråber er en sulfonamidhæmmer af karboanhydrase og absorberes systemisk på trods af lokal administration.
azopt is a sulphonamide inhibitor of carbonic anhydrase and, although administered topically, is absorbed systemically.

karboanhydrase (ca) er et enzym, som findes i mange væv i kroppen deriblandt øjet.
carbonic anhydrase (ca) is an enzyme found in many tissues of the body, including the eye.

azarga indeholder brinzolamid, en karboanhydrase-hæmmer som absorberes systemisk på trods af lokal administration.
azarga contains brinzolamide, a carbonic anhydrase inhibitor and, although administered topically, is absorbed systemically.

den samtidige behandling med azopt øjendråber og peroral karboanhydrase- hæmmere er ikke undersøgt og kan derfor ikke anbefales.
the concomitant administration of azopt and oral carbonic anhydrase inhibitors has not been studied and is not recommended.

brinzolamid er en hæmmer af karboanhydrase, som virker ved at blokere et enzym kaldet karboanhydrase, der producerer bikarbonationer i kroppen.
brinzolamide is a carbonic anhydrase inhibitor that works by blocking an enzyme called carbonic anhydrase, which produces bicarbonate ions in the body.

de samme typer uønskede virkninger, der kan skyldes orale karboanhydrase- hæmmere, kan opstå efter topikal administration.
the same type of undesirable effects that are attributable to oral carbonic anhydrase inhibitors may occur with topical administration.

de gastrointestinale, centralnervesystemiske, hæmatologiske, renale og metaboliske virkninger er normalt associeret med brug af systemiske karboanhydrase-hæmmere.
gastrointestinal, nervous system, haematological, renal and metabolic effects are generally associated with systemic carbonic anhydrase inhibitors.

ved at hæmme karboanhydrase i øjets ciliære processer nedsættes kammervæskesekretionen, formodentlig ved en langsommere dannelse af bikarbonationer, hvilket medfører en reduktion i natrium og væsketransport.
inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.

hos ældre patienter kan perorale karboanhydrase- hæmmere forringe evnen til at udføre opgaver, der kræver mental bevågenhed og/ eller fysisk koordination.
oral carbonic anhydrase inhibitors may impair the ability to perform tasks requiring mental alertness and/ or physical coordination in elderly patients.

samtidig behandling med azarga øjendråber og peroral karboanhydrase- hæmmere er ikke undersøgt og kan derfor ikke anbefales (se afsnit 4. 5).
the concomitant administration of azarga and oral carbonic anhydrase inhibitors has not been studied and is not recommended (see section 4.5).

der er en mulig additiv effekt af den kendte systemiske effekt af karboanhydrase- hæmmere hos patienter, som både behandles med en peroral karboanhydrase- hæmmer og azopt øjendråber.
there is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and azopt.

patienter med kontaktlinser er ikke blevet undersøgt, og forsigtighed med azopt anbefales, da karboanhydrase-hæmmere kan påvirke væsketilførslen til cornea.derfor har kontaktlinsebærere en øget risiko for skader på cornea.
specifically, patients wearing contact lenses have not been studied and careful monitoring of these patients when using brinzolamide is recommended, since carbonic anhydrase inhibitors may affect corneal hydration and wearing contact lenses might increase the risk for the cornea.

den anden var en 12-måneders undersøgelse, der havde til formål at sammenligne azarga med kombinationen af timolol og dorzolamid (en anden hæmmer af karboanhydrase) hos 437 patienter.
the second was a 12-month study comparing azarga with the combination of timolol and dorzolamide (another carbonic anhydrase inhibitor) in 437 patients.

brinzolamid er en hæmmer af karboanhydrase ii (ca-ii), det fremherskende isozym i øjet med et in vitro ic50 på 3,2 nm og et ki på 0,13 nm imod ca-ii.
brinzolamide, an inhibitor of carbonic anhydrase ii (ca-ii), the predominant iso-enzyme in the eye, with an in vitro ic50 of 3.2 nm and a ki of 0.13 nm against ca-ii.